Continuous ambulatory peritoneal dialysis (CAPD) is becoming the treatment of choice for many diabetics with end stage renal disease (ESRD). Hypertension is better controlled, neuropathy and vascular calcifications remains stable or improve, and few dietary or fluid restrictions are necessary. It is estimated that about 20% of all patients with ESRD will be using CAPD by 1985. Approximately 50 % of deaths in insulin dependent diabetics (and 6 ~o in insulin independent diabetics) 1 are due to renal failure. In general, diabetic patients appear to tolerate renal failure poorly. That is, they develop symptoms and complications of uremia at higher glomerular filtrations rates.2 2 Previously, diabetic patients were excluded from various treatments of end stage renal disease such as dialysis and transplantation because of the increased incidence of complications that include retinopathy, myopathy, neuropathy, peripheral vascular disease and cardio-vascular complications. Recently, however, more diabetic patients are being accepted into various transplant and dialysis programs. To date, survival rates and rehabilitation results have been discouraging for the end stage renal patient due to diabetes. At three years on hemodialysis, survival rates are approximately 35-50% compared to 75-85% survival in nondiabetics.' Blood glucose control in general is poor.' The majority of diabetic patients receiving hemodialysis tend to have a progression of their various other complications causing poor rehabilitation and often self